The Virginia-based biotech company, founded in 2016, has developed a core technology called Pantid that neutralizes the pathological component of patient antibody responses and destroys destructive immune cells, while leaving the patient's immune system functionality intact. Pantid targets autoreactive B cells that react to patient-endogenous proteins and uses protein fusions of B cell autoantigens to elicit targeted cell killing in autoreactive B cells. Orpheus Bioscience offers biotechnology companies the opportunity to develop PantIds through preclinical characterization, reverse-phase protein microarrays, and characterization of AD patient autoantibody responses.